The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species
Open accessPreprint — published as 10.1128/mbio.02502-24
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
In recent decades, there has been an increase in the occurrence of fungal infections, yet the arsenal of drugs available to fight invasive infections remains very limited. The development of new antifungal agents is hindered by the restricted number of molecular targets that can be exploited, given the shared eukaryotic nature of fungi and their hosts which often leads to host toxicity. In this paper, we examine the riboflavin biosynthetic pathway as a potential novel drug target. Riboflavin is an essential nutrient for all living organisms. Its biosynthetic pathway does not exist in humans, who obtain riboflavin through their diet. Our findings demonstrate that all enzymes in the pathway are essential for Candida albicans , Candida glabrata, and Saccharomyces cerevisiae. Among these enzymes, Rib1 and Rib3 are the most promising targets. Auxotrophic strains, which mimic a drug targeting the biosynthesis pathway, experience rapid mortality in the absence of supplemented riboflavin. Nevertheless, the cells can still take up external riboflavin when supplemented. We identified Orf19.4337 as the riboflavin importer in C. albicans and named it Rut1. We found that Rut1 only facilitates growth at external riboflavin concentrations that exceed the physiological concentrations in the human body, making it unlikely that riboflavin uptake to act as a potential resistance mechanism for a drug targeting the biosynthesis pathway. Interestingly, the uptake system in S. cerevisiae is more effective than in C. albicans and C. glabrata, enabling an auxotrophic S. cerevisiae strain to outcompete an auxotrophic C. albicans strain in lower riboflavin concentrations. Importance: Candida species are a common cause of invasive fungal infections. Candida albicans, in particular, poses a significant threat to immunocompromised individuals. This opportunistic pathogen typically lives as a commensal on mucosal surfaces of healthy individuals, but it can also cause invasive infections associated with high morbidity and mortality. Currently, there are only three major classes of antifungal drugs available to treat these infections. Additionally, the efficacy of these antifungal agents is restricted by host toxicity, suboptimal pharmacokinetics, a narrow spectrum of activity, intrinsic resistance of fungal species, such as Candida glabrata , to certain drugs, and the acquisition of resistance over time. Therefore, it is crucial to identify new antifungal drug targets with novel modes of action to add to the limited armamentarium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Research works printed but not linked: 53
- 10.1126/scitranslmed.3004404 · DOI · Paper page
- Clark C , Drummond RA . 2019. The Hidden Cost of Modern Medical Interventions: How Medical Advances Have Shaped the Prevalence of Human Fungal Disease. Pathogens 8. · DOI · Paper page
- 2020, Fungal infections in humans: the silent crisis, Microb Cell, 7, 143, 10.15698/mic2020.06.718 · DOI · Paper page
- 10.1016/S1473-3099(23)00692-8 · DOI · Paper page
- 10.1128/CMR.00029-06 · DOI · Paper page
- 10.1038/nrmicro.2016.157 · DOI · Paper page
- 10.1146/annurev-micro-091014-104330 · DOI · Paper page
- 10.1155/2014/615958 · DOI · Paper page
- Carolus H , Pierson S , Munoz JF , Subotic A , Cruz RB , Cuomo CA , Van Dijck P. 2021. Genome-Wide Analysis of Experimentally Evolved Candida auris Reveals Multiple Novel Mechanisms of Multidrug Resistance. mBio 12. · DOI · Paper page
- 10.1093/femsyr/fov025 · DOI
- Robbins N , Wright GD , Cowen LE . 2016. Antifungal Drugs: The Current Armamentarium and Development of New Agents. Microbiol Spectr 4. · DOI · Paper page
- Pierce CG , Srinivasan A , Ramasubramanian AK , Lopez-Ribot JL . 2015. From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms. Microbiol Spectr 3. · DOI
- 10.1126/science.aap7999 · DOI · Paper page
- 10.1517/17460441.2013.807245 · DOI · Paper page
- 2020, Production of Vitamin B2 (Riboflavin) by Microorganisms: An Overview, Front Bioeng Biotechnol, 8, 570828, 10.3389/fbioe.2020.570828 · DOI · Paper page
- 2023, Can we microbe-manage our vitamin acquisition for better health?, PLoS Pathog, 19, e1011361, 10.1371/journal.ppat.1011361 · DOI
- 10.1016/j.copbio.2012.08.005 · DOI · Paper page
- 10.1146/annurev.nutr.20.1.153 · DOI · Paper page
- 10.1016/j.sbi.2006.10.003 · DOI
- 10.1016/j.addr.2003.07.005 · DOI
- 10.1021/jo0703092 · DOI · Paper page
- 10.1039/c2np20069d · DOI · Paper page
- 10.1042/bst0160416 · DOI
- 10.1016/j.abb.2013.02.015 · DOI · Paper page
- 2020, Production of riboflavin and related cofactors by biotechnological processes, Microb Cell Fact, 19, 31, 10.1186/s12934-020-01302-7 · DOI · Paper page
- 2019, Understanding the riboflavin biosynthesis pathway for the development of antimicrobial agents, Med Res Rev, 39, 1338, 10.1002/med.21576 · DOI
- 10.1074/jbc.M505002200 · DOI
- Demuyser L , Palmans I , Vandecruys P , Van Dijck P. 2020. Molecular Elucidation of Riboflavin Production and Regulation in Candida albicans, toward a Novel Antifungal Drug Target. mSphere 5. · DOI
- 10.1080/21505594.2016.1213937 · DOI · Paper page
- 10.1016/j.gene.2004.06.021 · DOI · Paper page
- 10.1186/1471-2164-9-579 · DOI
- 10.3177/jnsv.54.423 · DOI
- 10.1146/annurev.mi.26.100172.002101 · DOI
- 1965, Flavin coenzymes, flavinogenesis and reproduction in Ashbya gossypii, J Biochem, 57, 773, 10.1093/oxfordjournals.jbchem.a128144 · DOI
- 10.1099/00221287-28-2-283 · DOI
- 2020, Expression of yeast homolog of the mammal BCRP gene coding for riboflavin efflux protein activates vitamin B(2) production in the flavinogenic yeast Candida famata, Yeast, 37, 467, 10.1002/yea.3470 · DOI
- 10.1093/NAR/GKAB1061 · DOI · Paper page
- 10.1093/nar/gky092 · DOI · Paper page
- 10.1128/JCM.06112-11 · DOI · Paper page
- 10.1101/gr.3672305 · DOI · Paper page
- 10.1074/jbc.M409581200 · DOI
- 10.1016/S0300-9084(02)01446-3 · DOI
- 10.1111/j.1742-4658.2008.06586.x · DOI
- 2022, Identification and Functional Analysis of GTP Cyclohydrolase II in Candida glabrata in Response to Nitrosative Stress, Front Microbiol, 13, 825121, 10.3389/fmicb.2022.825121 · DOI
- 10.1128/MMBR.00030-10 · DOI · Paper page
- 10.17226/6015 · DOI · Paper page
- Nguyen N , Quail MMF , Hernday AD. 2017. An Efficient, Rapid, and Recyclable System for CRISPR-Mediated Genome Editing in Candida albicans. mSphere 2. · DOI
- 10.1093/genetics/134.3.717 · DOI · Paper page
- Demuyser L , Swinnen E , Fiori A , Herrera-Malaver B , Vestrepen K , Van Dijck P. 2017. Mitochondrial Cochaperone Mge1 Is Involved in Regulating Susceptibility to Fluconazole in Saccharomyces cerevisiae and Candida Species. mBio 8. · DOI · Paper page
- 10.1002/yea.320110408 · DOI · Paper page
- 10.1038/nature02579 · DOI · Paper page
- 10.1038/nprot.2007.13 · DOI · Paper page
- 10.1080/09687680701342669 · DOI · Paper page
Metadata
- Authors
- Nysten, J., Peetermans, A., Vaneynde, D., Demuyser, L., & Van Dijck, P.
- Affiliations
- KU Leuven (BE)
- Venue
- mBio
- Publisher
- openRxiv
- Published
- 2024-03-01
- Volume
- 15
- Issue
- 11
- Pages
- e0250224-e0250224
- ISSN
- 2150-7511 (ISSN-L)
- PMC
- PMC11559065
- OpenAlex
- W4403406750
- Cited by
- 8
- References
- 1
- Citations by year
- 2026: 4 · 2025: 4
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- mBio (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Lirias (submittedVersion, cc-by-nc-sa)
- Chalmers Research (Chalmers University of Technology) (submittedVersion, cc-by-nc-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Fonds Wetenschappelijk Onderzoek (1S18121N, C14/22/075, 1S19219N, 11PRR24N)
- KU Leuven (C14/22/075)
- Onderzoeksraad, KU Leuven (C14/22/075)
- Vlaamse regering
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- riboflavin biosynthesis, antifungal drug targets, Candida albicans, Candida glabrata, Saccharomyces cerevisiae, riboflavin uptake, fungal virulence, invasive fungal infections, antifungal resistance
- MeSH terms
- Animals, Antifungal Agents, Candida albicans, Candidiasis, Disease Models, Animal, Fungal Proteins, Riboflavin, Saccharomyces cerevisiae, Virulence, Candida glabrata, Mice, Biosynthetic Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species. https://app.cochat.ai/papers/10.1101/2024.03.01.582991
- The paper
- Nysten, J., Peetermans, A., Vaneynde, D., Demuyser, L., & Van Dijck, P. (2024). The riboflavin biosynthetic pathway as a novel target for antifungal drugs against Candida species. mBio. https://doi.org/10.1101/2024.03.01.582991
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.